- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Understanding the Unmet Need for Therapies to Treat Rare Bile Duct Cancer
On this episode of Managed Care Cast, we bring you an excerpt of an interview with a co-chair of the 2022 Cholangiocarcinoma Foundation (CCF) annual conference, held earlier this year, about the significant unmet therapy needs facing most patients with this rare cancer.
Cholangiocarcinoma—or biliary duct cancer—affects about 8000 US patients a year. On this episode of Managed Care Cast, we bring you an excerpt of an interview with Jesper B. Andersen, PhD, associate professor and group leader at the University of Copenhagen and the Biotech Research and Innovation center at the Department of Health.
There have been 3 FDA drug approvals for drugs that treat cholangiocarcinoma, but these therapies are only for patients who have certain mutations or rearrangements, signifying an unmet need, noted Andersen. And due to the limited number of patients, clinical trials are challenging.
Andersen was a co-chair of the 2022 Cholangiocarcinoma Foundation (CCF) annual conference, held earlier this year. He spoke after the conference with Brielle Benyon, senior editor of CURE®, a publication by MJH Life Sciences®.
You can watch the interview in its entirety on Medical World News.
Listen above or through one of these podcast services:
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Falls, Balance Issues Signal Higher ICANS Risk in NHL
February 28th 2025Adverse physical functions were indicative of reduced survival and increased risk of immune effector cell–associated neurotoxicity syndrome (ICANS) in patients with non-Hodgkin lymphoma (NHL) previously treated with chimeric antigen receptor T-cell therapy.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
